Gujral, et al.: Dexmedetomidine in peribulbar block for vitreoretinal surgery

Commentary: Role of alpha-2 agonists in regional ophthalmic anaesthesia
Regional anaesthesia is the most common mode of anaesthesia used in ophthalmic surgical procedures. Among regional blocks, peribulbar anaesthesia is the safest and most commonly employed. However, in procedures with prolonged operating time, such as vitreoretinal surgeries, repeated need for block supplementation and patient anxiety, are a challenge. Adjuvants to peribulbar anaesthetics, namely, hyaluronidase and adrenaline along with preoperative anxiolytics/sedatives have been tried to overcome these challenges. [1] Alpha-2 agonists are drugs which bind selectively to alpha-2 adrenergic receptors in the central, peripheral and autonomic nervous system as well as in vital organs and blood vessels. They produce dose-dependent analgesia, anxiolysis and sedation without causing respiratory depression by acting on the G protein-coupled alpha-2 receptors. [2] Two main alpha-2 agonists that are commercially available include clonidine and dexmedetomidine. Although neither of them is completely selective for alpha-2 receptors, dexmedetomidine is 8-10 times more selective towards these receptors compared to clonidine. Dexmedetomidine has a higher avidity and affinity for alpha-2 receptors, shorter elimination half-life and higher clinical efficacy with a lesser side-effect profile compared to clonidine. [3] The study by Gujral et al. adds credence to the anxiolytic effect of dexmedetomidine which is coupled with hemodynamic safety in patients receiving peribulbar block for vitreoretinal surgery. [4] Clonidine was the first alpha-2 agonist to be used as an adjuvant by Mjahed et al. who found that its addition to peribulbar block decreased intraocular pressure, enhanced anaesthesia, akinesia and intraoperative sedation. [5] However, use of clonidine was associated with hemodynamic side-effects such as bradycardia, arterial and orthostatic hypotension, rebound hypertension and syncope. The long half-life of clonidine meant that the hemodynamic instability was not only seen intra-operatively but also for up to 8 hours in the post-operative period. [6] Dexmedetomidine, a newer alpha-2 agonist, has shown potential with a better safety profile due to its higher selectivity and shorter half-life. Two recent studies have evaluated its efficacy and side-effect profile when used as an adjunct to peribulbar block during vitreoretinal surgery. [7, 8] Ahmed et al. [7] used 20 µg of dexmedetomidine along with lidocaine, bupivacaine and hyaluronidase. They found faster onset of anaesthesia, akinesia, increased duration of anaesthesia and increased patient sedation in comparison to a control group using normal saline. EL-Shmaa et al. [8] compared two doses of dexmedetomidine, 15 and 30 µg, as adjuvants to routine peribulbar anaesthetic agents. They also found similar results in terms of onset and duration of anaesthesia in the dexmedetomidine groups compared with the control group. The two doses did not differ significantly in terms of their efficacy or side-effect profile. The current study in contrast did not find any difference in the time of onset of anaesthesia between the study and the control groups; however, the patient and surgeon comfort were significantly better with dexmedetomidine. This study is also unique in keeping the systemic stability as its primary outcome measure. [4] No significant systemic side-effects have been reported with either of the studies while using this drug in vitreoretinal surgeries.
There is increasing evidence that supports the use of dexmedetomidine as an adjunct to regional blocks for ophthalmic anaesthesia. This drug seems to be especially useful in cases with prolonged operating times such as complex vitreoretinal surgeries and for apprehensive patients. However, use of dexmedetomidine in patients with heart block, heart failure, renal/hepatic insufficiency, uncontrolled diabetes, obesity and/or chronic obstructive pulmonary disease is contraindicated. Meticulous pre-operative evaluation by the anaesthesia team is thus essential before subjecting a patient to peribulbar block with dexmedetimidine as an additive. Establishment of standard pre-anaesthetic evaluation and intra-operative monitoring protocols are needed before this drug gains popularity as an adjunct for regional anaesthesia in ophthalmic surgery. Hence, further studies on the requirement of systemic monitoring during surgery and long-term safety profile of these agents are warranted.
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Commentary: Adjunctive agents in peribulbar anesthesia: Role of dexmedetomidine in vitreo-retinal surgeries
Cataract surgery is increasingly becoming a refractive surgery being done under topical anesthesia. In Indian scenario, where majority of the surgical patients reside in rural area, peribulbar anesthesia (PA) for cataract surgery is a major facilitator. Why so? Topical anesthesia requires cooperation from patient and issues, such as hearing difficulty, old age, poor comprehension, and language difference can aggravate the barrier of doing surgery under topical anesthesia.
PA is being given either with lignocaine alone or lignocaine plus bupivacaine mixture. Surgeons operating the volume would agree that many times the PA does not take adequate effect even after proper technique and multiple injections or the effect is only partial or akinesia reduces or the effect goes off in between surgery. The question "why the effect of the block is weak" or "why the effect has weaned off so soon" remains largely unanswered. Thus, the addition of an agent that can improve the final result of the peribulbar block has always been welcomed.
Various agents, such as midazolam, hyaluronidase, rocuronium, and dexmedetomidine (Dex), have been tried and shown to have a beneficial effect either on the onset time or the duration of the block. In an randomized control trial (RCT) by Ibrahim et al., [1] midazolam was used as an adjunct to the mixture of bupivacaine 0.5% and lidocaine 2%; it was noted that addition of midazolam improved the onset of anesthesia and prolonged the duration of lid akinesia and sensory anesthesia but did not have any additional effect on the onset of akinesia or the duration of globe akinesia. Ibrahim et al. [1] did not use midazolam in systemic form. Hyaluronidase was also tested by Swati et al. [2] in a randomized double-blind study but did not prove to be beneficial in any sense. Rocuronium, a neuromuscular blocking agent, was also tried by Patil et al. [3] and found to have a beneficial effect on the onset of akinesia but no effect on anesthesia. Dex [4] has been tried in both infusion and local mixture form and found to have early onset, prolonged duration of the block, and better hemodynamic stability.
All these studies [1] [2] [3] [4] have been done in cataract surgery, which generally gets over in few minutes. Other ocular surgeries that take more time are vitreo-retinal surgery, keratoplasty, oculoplasty, etc., Early onset, prolonged duration of PA, and non-requirement of a supplementary block will be very useful in such surgeries. In addition to adequate block effect, a hemodynamically stable patient during such prolong surgeries will improve the surgeon efficacy many folds. A study done by Abdelhamid et al. concluded that addition of IV infusion of Dex resulted in a better sedation profile along with vital stability during the surgery. Dex is a selective alpha-2 adrenoreceptor agonist that provides dose-dependent sedation and analgesia without relevant respiratory depression. Although IV infusion along with the supplementation in the peribulbar block proved to be beneficial; 2 patients suffered bradycardia as a result of a systemic complication of Dex.
In the current issue of Indian Journal of Ophthalmology, Ganganjeet et al. [5] have very efficiently evaluated the role of Dex in PA in vitreo-retinal surgeries under "Evaluation of the effect and safety of Dexmedetomidine as an additive to local anesthesia in peribulbar block for vitreoretinal surgery." A prospective randomized study comparing the usefulness of Dex in PA in vitreo-retinal surgeries has not been done so far. The authors have avoided the use of IV infusion; thus, eliminating the undue systemic risk. Multiple systemic and ocular parameters were taken into account. Although it was not significantly different, the addition of 20 µg of Dex resulted in the early onset of anesthesia. Supplementation requirement of the block was also clinically lower in Dex group. More importantly, the Dex group showed a better pain and sedation profile with most patients being comfortable till the end of the surgery. Systemic parameters, such as systolic blood pressure and mean arterial pressure, showed a hypotensive pattern in comparison to the control group, which can be of great help to the surgeon during surgeries, such as diabetic vitrectomies, where chances of intraocular bleed are much more.
In comparison to the study conducted by Abdelhamid et al. where IV infusion of Dex lowered the heart rate, no such effect was seen in the present study. Also, the surgeon satisfaction level was higher probably due to better sedation and anesthesia profile.
In conclusion, among the many adjunctive agents used till now, Dex has proved its non-inferior role in terms of 
